Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE NeoGenomics, Inc.
Alliance provides Aurora with a broad array of oncology specialty testing to complement its current anatomic pathology services in dermatology, gastroenterology, urology and women's health
FT. MYERS, Fla., May 8, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today that it has been selected by Aurora Diagnostics to be its primary partner for molecular testing at each of Aurora's 19 specialized anatomic pathology laboratories in the United States.
As a result of this alliance, Aurora will be able to standardize advanced oncology-focused molecular testing services to support the needs of their referring physicians. NeoGenomics gains the opportunity to provide its molecular and genetic oncology test offerings through Aurora Diagnostics' extensive network of Physicians to help deliver the highest level of patient care.
Bruce Walton, Executive Vice President of Aurora, stated, "Aurora's Molecular Medical Advisory Committee unanimously decided to partner with NeoGenomics after carefully considering a number of high-quality diagnostic laboratories. Our committee evaluated quality-of-testing, breadth and depth of services, information technology capabilities, managed care access, product development pipeline, and future partnership opportunities. We are thrilled to have selected NeoGenomics to provide Aurora's 110 licensed physicians with access to NeoGenomics fully integrated anatomic pathology and histology services."
Douglas VanOort, NeoGenomics Chairman and CEO, stated, "Aurora Diagnostics is one of the largest Anatomic Pathology organizations in America with a very strong reputation for quality. Having served several of Aurora's regional laboratories in the past, we are now particularly pleased to enter into this broader alliance. We believe our oncology-focused genetic and molecular testing services are a perfect complement to Aurora's extensive laboratory services, and we look forward to combining our capabilities for the benefit of Aurora's clients and their patients across America.
About Aurora Diagnostics
Aurora Diagnostics is a specialized laboratory company focused on anatomic pathology at 19 locations within the United States. Employing over 110 licensed physicians, Aurora Diagnostics provides high-quality diagnostics and testing information for the patients of its primary referral sources-dermatologists, OB/GYN professionals, gastroenterologists, urologists, general surgeons, oncologists, and over 50 community-based hospitals. For additional information regarding Aurora Diagnostics and the services it provides, please visit the company website at www.auroradx.com.
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that specializes in cancer genetics testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA, Tampa, FL and Fort Myers, FL. NeoGenomics services the needs of pathologists, oncologists, urologists and other clinicians, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.com.
Forward Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements. Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.
©2012 PR Newswire. All Rights Reserved.